Press Release | Newsroom | Medtronic | Medtronic TYRX(TM) Antibacterial Envelope Reduces Cardiac Device Infection Rates at 12 Months

Press Release

Printer Friendly Version View printer-friendly version
Download PDF Download PDF
<< Back
Medtronic TYRX(TM) Antibacterial Envelope Reduces Cardiac Device Infection Rates at 12 Months

Medtronic, Inc.

Long-term Citadel/Centurion Clinical Trial Findings and Independent Data Presented at Heart Rhythm Society 36th Annual Scientific Sessions

DUBLIN and BOSTON - MAY 15, 2015 - Medtronic plc (NYSE: MDT) today announced that its TYRX(TM) Antibacterial Envelope reduces major cardiac device site infections by 80 percent, up to 12 months after implantation. These data were presented at Heart Rhythm 2015, the Heart Rhythm Society's 36th Annual Scientific Sessions in Boston.

The Citadel/Centurion Clinical Trials are the first prospective, multicenter studies to evaluate the impact of the TYRX Antibacterial Envelope on cardiac implantable electronic device (CIED) major infections and mechanical complication rates following implantation in high-risk patients. The results show a low rate of surgical site infection at 12 months (0.44 percent) in the 1,129  patients who received the TYRX Antibacterial Envelope compared with a control group of similar patients reported in previously published literature1 who did not receive an envelope (2.2 percent; p=0.0023).

CIED infections are associated with substantial morbidity, mortality and cost2,3,4 and are increasing in frequency. The average cost of a CIED infection in the United States is estimated at $54,926.5

"Clinical studies show that the use of the TYRX Envelope is associated with a significant reduction in implant-related cardiac device site infections," said Charles A. Henrikson, M.D., M.P.H., FHRS, chief of electrophysiology at Oregon Health & Science University in Portland. "These new findings reveal that the TYRX Envelope decreases the rate of infections that can occur within the first year after implantation. This is very good news for patients, especially given the associated mortality and costs tied to CIED infection."

12-Month Results of Citadel/Centurion Clinical Trials
The Citadel/Centurion Clinical Trials enrolled 1,129 patients at 55 centers in the United States. Study participants were at high risk for infection because they were undergoing a CIED replacement procedure with either an implantable cardioverter-defibrillator (ICD) (Citadel) or a cardiac resynchronization therapy (CRT) device (Centurion). Primary endpoints were major CIED infection (involving any site other than skin or subcutaneous tissue of the incision, or endocarditis) and CIED mechanical complication over 12 months of follow-up. The frequency of CIED mechanical complications in patients implanted with the TYRX Envelope was low.

"These data support the long-term safety and efficacy of the TYRX Envelope and showcase the clinical benefit of this novel technology for cardiac device patients at increased risk for infection," said Marshall Stanton, M.D., vice president and general manager of the Tachycardia business, which is part of the Cardiac and Vascular Group at Medtronic.

Results of Independent Study of TYRX(TM) Absorbable Antibacterial Envelope
Additionally at Heart Rhythm 2015, researchers at Vanderbilt University Medical Center independently reported that the TYRX(TM) Absorbable Antibacterial Envelope was associated with a very low incidence of CIED-related infection in a high-risk population, comparable to that seen with the original non-absorbable TYRX Antibacterial Envelope.

"Our study is the first-of-its-kind, comparing the incidence of major cardiac device-related infection in high-risk patients who, during implantation, received either the TYRX Absorbable Envelope or the non-absorbable Envelope, with a control group of patients who did not receive a TYRX envelope," said Christopher R. Ellis, M.D., FHRS, FACC, principal investigator of the study and assistant professor of medicine at Vanderbilt University Medical Center. "After a minimum of three months, results showed only one reported infection in the 488 patients who received either the original or newer, absorbable TYRX Envelope, compared with 20 infections in the control group of 638 patients. Additionally, it was encouraging to find no difference in infection rates between the original TYRX Envelope and the newer, fully absorbable version."

About CIED Infections
CIED infections occur in 1-7 percent6 of all CIED patients and about 3 percent of high-risk patients. High-risk patients include those patients with diabetes, with a previous history of infection, having a revision or upgrade procedure, or with renal failure or congestive heart failure. Most CIED site infections occur within the first three months. However, bacteria introduced during the implant can lay dormant in the subcutaneous pocket that houses the device under the skin and cause a delayed infection six months or more after implantation.

About the TYRX Antibacterial Envelope
The TYRX Antibacterial Envelope is a mesh envelope that holds an implantable cardiac device and is designed to stabilize the device after implantation while releasing two antimicrobial agents, minocycline and rifampin, over a minimum of seven days to help reduce surgical-site infections.

The TYRX Absorbable Antibacterial Envelope is fully absorbed by the body approximately nine weeks after implantation. Both TYRX Envelopes are FDA-cleared and have received CE Mark and are available in the United States and Europe.

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.

About Medtronic
Medtronic plc (, headquartered in Dublin, Ireland, is the global leader in medical technology - alleviating pain, restoring health and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

- end -

1 Gould, et al. Outcome of advisory implantable cardioverter-defibrillator replacement: one-year follow-up. Heart Rhythm, 2008; 5(12):1675-81.

2 Sohail MR, Henrikson CA, Braid-Forbes MJ, et al. Mortality and cost associated with cardiovascular implantable electronic device infections. Arch Intern Med 2011; 171:1821-1828.

3 Le KY, Sohail MR, Friedman PA, Uslan DZ, et al. Impact of timing of device removal on mortality in patients with cardiovascular implantable electronic device infections. Heart Rhythm 2011; 8: 1678-1685.

4 Habib A, Le KY, Baddour LM, et al. Predictors of mortality in patients with cardiovascular implantable electronic device infections. Am J Cardiol 2013; 111:874-879.

5Shariff NEby EAdelstein E, et al. J Cardiovasc Electrophysiol. Health and Economic Outcomes Associated with Use of an Antimicrobial Envelope as a Standard of Care for Cardiac Implantable Electronic Device Implantation. 2015 Apr 6. doi: 10.1111/jce.12684. [Epub ahead of print]
6 Tarakji KGChan EJCantillon DJ, et al. Cardiac implantable electronic device infections: presentation, management, and patient outcomes. Heart Rhythm. 2010 Aug;7(8):1043-7.


Tracy McNulty
Public Relations

Jeff Warren
Investor Relations